Synthesis and Study of Anti‐HIV Drugs

The human immunodeficiency virus (HIV) pandemic is one of the most serious health challenges humanity is facing today. There are 25 drugs approved for the treatment of HIV and acquired immune deficiency syndrome (AIDS). Nevertheless, HIV continues to infect and kill millions of people every year. However, the emergence of drug resistant HIV variants during treatment remains a problem for permanent treatment success and seriously hampers the composition of new active regimens. HIV is the probable causative agent of AIDS, which is one of the world’s most serious health problems. Several biological processes in the life cycle of this virus have been targeted for anti-HIV therapy. In order to combat the debilitating disease AIDS, the USA FDA has approved new drugs for the treatment of HIV infection. These drugs include nucleoside analogue HIV reverse transcriptase (RT) inhibitors, non-nucleoside RT inhibitors, and protease inhibitors. However, the efficacy of these HIV enzyme inhibitors is limited by the development of drug resistance and their toxic side effects. Thus, current anti-HIV drug discovery is largely focused on new 2,4,6-triazine derivatives with novel mechanisms of action.